VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LABStandard BioTools Inc.
$0.54$223M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. LAB
  4. Financial Ratios

Standard BioTools Inc. (LAB) Financial Ratios

Latest Ratios: P/E Ratio -5.7x · EV/EBITDA N/A · ROE -16.7%. (2006–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

LAB Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$223M$488M$617M$175M$92M$297M$432M$232M$342M$194M$211M
Enterprise Value$136M$401M$483M$221M$113M$380M$459M$271M$418M$331M$371M
P/E Ratio →-5.72——————————
P/S Ratio2.645.723.541.650.942.283.131.983.031.912.02
P/B Ratio0.511.151.31——3.143.111.514.746.283.97
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

LAB EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—4.702.772.081.152.913.322.313.703.253.55
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

LAB Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin49.9%49.9%48.3%47.4%37.8%53.1%60.3%54.8%54.6%51.0%55.9%
Operating Margin-109.3%-109.3%-100.5%-72.0%-118.6%-51.7%-36.9%-44.2%-42.6%-57.3%-70.1%
Net Profit Margin-87.8%-87.8%-79.6%-70.2%-194.1%-45.4%-38.4%-55.3%-52.2%-59.4%-72.8%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-16.7%-16.7%-85.8%—-2895.8%-50.7%-36.2%-57.4%-114.5%-143.8%-90.4%
ROA-12.7%-12.7%-29.7%-20.9%-57.1%-19.7%-18.0%-22.8%-20.0%-20.4%-22.4%
ROIC-20.7%-20.7%-111.2%—-148.1%-29.4%-21.4%-22.8%-22.8%-23.0%-22.2%
ROCE-18.6%-18.6%-46.1%-27.3%-40.6%-27.2%-20.3%-20.8%-18.5%-22.0%-23.7%

LAB Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.070.070.07——1.180.690.392.396.313.66
Debt / EBITDA———————————
Net Debt / Equity—-0.21-0.28——0.880.190.251.064.433.00
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-3718.31-3718.31-40.71-15.25-43.55-15.65-14.15-14.59-3.42-9.95-12.78

Net cash position: cash ($118M) exceeds total debt ($31M)

LAB Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.194.195.701.454.811.452.172.933.382.833.28
Quick Ratio4.014.015.091.264.311.031.812.503.042.382.60
Cash Ratio1.731.734.441.053.820.571.261.792.541.892.01
Asset Turnover—0.150.280.330.250.470.430.440.370.350.34
Inventory Turnover2.142.142.212.722.842.942.783.813.953.312.29
Days Sales Outstanding—57.4570.3267.4864.3951.2167.1759.0953.8053.8951.06

LAB Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%6.6%3.1%0.8%0.6%0.0%0.3%0.0%0.0%0.1%
Total Shareholder Yield0.0%0.0%6.6%3.1%0.8%0.6%0.0%0.3%0.0%0.0%0.1%
Shares Outstanding—$382M$353M$79M$78M$76M$72M$67M$40M$33M$29M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Persistent operating losses and cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Discount to Book Reflects Earnings Doubt

Based on reported figures, LAB trades at 0.57 times book value and 2.92 times sales, a discount to book that suggests the market is pricing in continued losses and possible asset impairment rather than an earnings recovery.

With trailing P/E at -3.18 and no positive earnings base to anchor EV/EBITDA, price-to-book and price-to-sales are the only usable valuation signals, and the negative operating margin of -102.0% in 2026Q3 limits their reliability. The sub-1.0 P/B, set against a shrinking asset base and retained earnings near -$1.1B, may indicate that investors doubt the book value of equity will be realized through operations. Investors should monitor whether quarterly revenue stabilization near $19M to $21M can translate into positive operating income before the multiple can be considered meaningful.

Positive Net Margin Is Non-Operating Noise

As reported in the income statements, LAB posted a 69.6% net margin in 2026Q3 while its operating margin stayed at -102.0%, indicating the bottom-line result is driven by items outside core operations rather than improved earning power.

Gross margin ranged between 43.0% and 55.9% across the ten quarters, which is respectable for a tools business, yet operating margin has remained deeply negative throughout, so gross profit is consistently consumed by operating expenses. The 2026Q3 net margin reversal from -133.1% in the prior quarter to +69.6% appears to reflect non-recurring or non-operating gains and should not be read as evidence of sustainable profitability. Operating margin remains the more reliable measure of earning power here, and it is firmly negative.

Negative ROIC Persists Despite Asset Shrinkage

Based on LAB's reported quarterly figures, ROIC has remained negative across all ten quarters, ranging from -2.1% to -7.0%, suggesting the company has not yet generated returns above its cost of capital on the invested base.

The shrinking asset base and declining debt have not translated into improving returns, indicating that capital is being consumed faster than it is being redeployed productively. ROE swung between -9.2% and +4.7% without a sustained upward trend, which implies equity returns are driven more by volatile non-operating results than by operating improvement. Until operating margins turn positive, ROIC is unlikely to recover durably, and investors should monitor whether asset reduction stabilizes the denominator.

Low Leverage Offsets Absent Interest Coverage

As reported in the balance sheets, LAB's debt-to-equity fell from 0.18 in 2024Q3 to 0.05 in 2026Q3, yet interest coverage is not meaningful given negative operating income, so debt service capacity cannot be assessed from earnings.

Debt has been reduced substantially, which lowers refinancing and covenant pressure relative to the prior period, making this the most favorable leverage trend in the dataset. Interest coverage ratios are either blank or deeply negative, so the company cannot service debt from operating earnings and must rely on its cash balance of roughly $267.5M. Because the data does not disclose debt maturities or covenant terms, any conclusion about refinancing risk remains speculative and warrants further investigation.

Cash Cushion Thins Under Sustained Burn

Based on reported figures, LAB's current ratio of 9.75 and quick ratio of 9.40 in 2026Q3 appear strong, but these levels rest on a cash balance that declines with each quarter of operating cash outflow.

The high current ratio is largely supported by cash and receivables relative to $79.6M of total liabilities, which makes near-term liquidity look substantial on a static basis. Operating cash outflows in most quarters, including -$56.9M in 2026Q2, mean the cushion is being drawn down rather than replenished, and a 185-day cash conversion cycle in 2026Q3 suggests working capital is tied up for long periods. Under continued burn at prior-year rates, the liquidity runway would shorten meaningfully, so investors should monitor quarterly cash movement closely.

Headline Liquidity Overstates Durable Strength

As reported in the balance sheets, LAB's 9.75 current ratio may overstate resilience, since the ratio is supported by a cash balance that is being consumed by operating outflows and a retained deficit near -$1.1B.

A bullish reading would point to the 0.05 debt-to-equity and the 9.75 current ratio as evidence of a fortress balance sheet, but these figures describe a snapshot rather than a durable earnings base. The deficit suggests equity has been funded largely by paid-in capital, which may understate future dilution exposure if burn persists. Investors should weigh whether the cash runway, not the static ratios, is the binding constraint on the equity thesis.

Download Financial Ratios Data

Includes 30+ ratios · 20 years · Updated daily

Consensus & Technical Research Suite
Open LAB Terminal

LAB Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LAB — Frequently Asked Questions

Quick answers to the most common questions about buying LAB stock.

What is Standard BioTools Inc.'s P/E ratio?

Standard BioTools Inc.'s current P/E ratio is -5.7x. This places it at the 50th percentile of its historical range.

What is Standard BioTools Inc.'s ROE?

Standard BioTools Inc.'s return on equity (ROE) is -16.7%. The historical average is -58.3%.

Is LAB stock overvalued?

Based on historical data, Standard BioTools Inc. is trading at a P/E of -5.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Standard BioTools Inc.'s profit margins?

Standard BioTools Inc. has 49.9% gross margin and -109.3% operating margin.